Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma

A. Boiardi, A. Silvani, I. Milanesi, M. Botturi, G. Broggi

Research output: Contribution to journalArticlepeer-review


The aim of this study was to verify the tolerability and efficacy of therapeutic chemotherapy protocols, employing different combinations of cis-platin, carbo-platin, etoposide and carmustine in primary glioblastoma patients. The purpose was focused on 2 end points: the response index to treatment, the TTP (tumor progression) and the ST (survival time). Eighty-four out of a group of 99 consecutive glioblastoma patients, entered this study. Patients were divided into 4 disparate treatment groups: (A) BCNU alone; (B) CDDP+VP-16; (C) CBDCA+BCNU; (D) CBDCA+BCNU+VP-16. The effectiveness and the TTP of the protocols differed, but differences were not statistically significant. Data concerning platinum treatment compare favorably with the best literature results. At 18 months more than half the carboplatin-treated patients are alive. Moreover these patients had a significantly longer ST than those treated with BCNU. We conclude that platinum-based chemotherapy has a beneficial effect on glial tumors.

Original languageEnglish
Pages (from-to)717-722
Number of pages6
JournalItalian Journal of Neurological Sciences
Issue number9
Publication statusPublished - Dec 1992


  • chemotherapy
  • Glioblastoma
  • platinum

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma'. Together they form a unique fingerprint.

Cite this